O16-2 Phase I trial of NY-ESO-1 TCR-T cell therapy combined with nanoparticulate vaccine but without lymphodepletion for STS

Mikiya Ishihara,Yoshihiro Nishida,Shigehisa Kitano,Akira Kawai,Naozumi Harada,Yoshihiro Miyahara,Hiroyoshi Hattori,Kohichi Takada,Makoto Emori,Shigeki Kakunaga,Makoto Endo,Yoshihiro Matsumoto,Tetsuro Sasada,Eiichi Sato,Tomomi Yamada,Akihiko Matsumine,Yasuhiro Nagata,Shinichi Kageyama,Hiroshi Shiku

Annals of Oncology（2023）

Cited 0|Views11

No score

Abstract

We conducted an investigator-initiated, multi-institutional first-in-human phase I clinical trial of a NY-ESO-1-specific TCR engineered T cell (TBI-1301) combined with a T cell stimulator CHP:NE1 for patients with NY-ESO-1-expressing advanced soft tissue sarcoma (STS).

Translated text

Key words

nanoparticulate vaccine,lymphodepletion,ny-eso

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined